SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-221784
Filing Date
2024-09-19
Accepted
2024-09-19 08:10:32
Documents
16
Period of Report
2024-09-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d809647d8k.htm   iXBRL 8-K 27196
2 EX-99.1 d809647dex991.htm EX-99.1 12025
7 GRAPHIC g809647g0919163644387.jpg GRAPHIC 4187
  Complete submission text file 0001193125-24-221784.txt   210395

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240919.xsd EX-101.SCH 4191
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20240919_def.xml EX-101.DEF 13768
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240919_lab.xml EX-101.LAB 22889
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240919_pre.xml EX-101.PRE 14736
18 EXTRACTED XBRL INSTANCE DOCUMENT d809647d8k_htm.xml XML 5942
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 241309134
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)